Gastric Fungal Colonization as a Candidate Mechanism in ALS-Spectrum Motor Neuron Disease: A Hypothesis Supported by Five Years of Case Documentation

1. Introduction

In a small mountain village in the French Alps, 14 people developed ALS between 1990 and 2018. Statistically, one case would have been expected. No shared genetic factor was identified. All affected individuals had consumed wild-harvested fungi with documented neurotoxic potential. The cluster was published in 2021 in the Journal of Neurological Sciences [2].

Andrew Reid had proposed the connection earlier. As far back as 2006 — republished in 2021 — he documented consistent Trichothecene elevation and global immunosuppression across ALS patients he examined, with T-2 toxin as the central finding [3]. He interpreted ALS, at least in a subset of cases, as a consequence of mycotoxin exposure and secondary immune paralysis.

The third data point comes from pharmacovigilance. Ustekinumab — a monoclonal antibody against IL-12 and IL-23 — suppresses TH1 and TH17, the immune system’s primary antifungal axes. A disproportionality analysis of the FDA Adverse Event Reporting System identified an elevated reporting signal for ALS in association with ustekinumab [4]. When antifungal immune defenses are pharmacologically removed, the risk of motor neuron disease appears to rise.

Three independent observations. No shared methodology. The same direction: fungi → toxins → neurotoxicity → motor neuron damage.

The present hypothesis proposes a mechanism that unifies these observations. A mold concealed behind a mucosal biofilm in the gastric fundus continuously produces Trichothecene mycotoxins. These mycotoxins activate pattern recognition receptors on vagal afferent fibers running through the gastric wall — fibers that project, via the Nucleus tractus solitarius, into adjacent brainstem motor nuclei. Under sustained activation, this afferent signal does not remain contained: it spills over into neighboring motor circuits and establishes itself as the tonic input on which motor neurons depend to remain active. Remove the mycotoxins — remove the signal. The motor neurons, calibrated to that input as their functional baseline, degenerate not from being attacked, but from being abandoned.

This mechanism operates alongside a second: a cross-reactive immune attack on motor-neuron surface proteins, driven by T cells primed against fungal antigens or by immune responses modified by mycotoxin exposure. And a third: acute Dectin-1-mediated neuroinflammation when the biofilm periodically ruptures and beta-glucan is exposed.

The following sections describe the proposed mechanism in full, the five-year case documentation on which it is based, and the supporting evidence from the published literature.

2. The Hypothesis

Interpretive framework. The mechanistic relationships proposed in this section are hypothesis-based interpretations of the documented observations and cited literature. Unless explicitly identified as an established finding, statements concerning causality, receptor involvement, anatomical signal propagation, fungal colonization, biofilm disruption, immune cross-reactivity, and treatment implications should be understood as testable components of the proposed model rather than as established biological or clinical facts.

2.1. The First Trigger: Vagal Afferent Overactivation and Neural Spill-Over to Motor Nuclei

Level 1 — Tension

The gastric mucosa is densely innervated by afferent fibers of the vagus nerve — sensory fibers that carry signals from the upper gastrointestinal tract to the brainstem via the Nucleus tractus solitarius (NTS). These fibers express pattern recognition receptors of the innate immune system, including TLR4 as the primary candidate and TRPV1 as an alternative [6,20]. Under physiological conditions, they transmit low-level input reflecting the local mucosal environment. Under the proposed model, a biofilm-protected fungal colonization of the gastric mucosa transforms this input permanently.

Circulating Trichothecene mycotoxins — continuously produced and absorbed from behind the biofilm — activate TLR receptors on vagal afferent neurons directly. Simultaneously, fungal PAMPs (particularly beta-1,3-glucan and fungal RNA fragments leaking through or around the biofilm) activate the same receptors on mucosal nerve endings. The result is sustained, high-amplitude afferent firing along vagal fibers that project into the NTS — far exceeding the low-level tonic input these fibers normally carry.

This is where the spill-over occurs. The NTS sits in the dorsal brainstem in immediate anatomical proximity to motor nuclei — including the dorsal motor nucleus of the vagus, the nucleus ambiguus, and the hypoglossal nucleus. Under sustained high-amplitude afferent input, excitatory signals do not remain contained within the NTS but radiate into adjacent motor neuron populations. The proposed effect could involve directed immune signaling, molecular mimicry, anatomical convergence, or a combination of these mechanisms, with afferent overload generating tonic excitation in neighboring motor circuits.

The observed pharmacological evidence is consistent. A TLR-modulating marine polysaccharide (Fucoidan) produced complete collapse of muscle tension within five minutes, with simultaneous onset of weakness. Omega-3 fatty acids produced an identical response. Two structurally unrelated substances produced similar immediate effects. When the afferent input is blocked — whether via TLR4 antagonism or direct mycotoxin sequestration — the tonic motor excitation disappears. The muscle loses tension because the signal maintaining its tone has been cut.

This reframes what the Trichothecene mycotoxins are doing to the nervous system. They are not merely toxic. They may have become a major source of afferent input to which the motor neurons have partially adapted. A motor neuron exposed to sustained, high-amplitude vagal input for months or years may calibrate its activity threshold to that input, effectively adopting it as a functional baseline, a process consistent with established principles of homeostatic plasticity in neural circuits [23,24]. Mycotoxin-driven afferent firing may no longer represent merely an additional pathological stimulus to an otherwise intact system. It has replaced the system’s normal input.

The consequence is direct: remove the mycotoxins, remove the fungus, and the afferent signal collapses. The motor neuron, calibrated to sustained excitatory input, receives nothing. The neuromuscular junction falls silent. The muscle atrophies. Within the proposed model, this sequence may also offer a possible explanation for the observations in Montchavin: the patients were exposed to neurotoxic fungi, the toxins arrived, vagal afferent overload began, and when the exposure ended, the proposed protective signal ended as well.

2.2. The Second Trigger: Cross-Reactive Immune Attack on Motor Neurons

Level 2 — Hyperstimulation

The neural spill-over described in Section 2.1 is not the only mechanism maintaining motor neuron excitation. A second, immunologically driven component operates in parallel — and the two can be distinguished pharmacologically.

T-cells primed against fungal antigens are proposed to cross-react with surface proteins on motor neurons. The underlying phenomenon — molecular mimicry — is well documented in autoimmune disease: in Guillain-Barré syndrome, T-cells targeting Campylobacter ganglioside structures attack peripheral nerve myelin carrying similar epitopes [22]; in multiple sclerosis, viral antigens trigger cross-reactive responses against myelin basic protein [9]. The proposed mechanism follows the same logic: fungal surface structures and motor-neuron surface proteins may share sufficiently similar epitopes for an immune response directed against the fungal colonization to cross-react with the neurons.

This immune-mediated component is proposed to provide a second source of excitatory input to motor neurons, distinct from the vagal afferent signal. Where the neural mechanism operates through anatomy (overloaded afferent input radiating into adjacent motor circuits), this mechanism operates through antigen recognition: T-cells misidentifying motor neuron surface proteins as fungal targets and maintaining the neuron in a state of chronic immune overstimulation.

The two mechanisms are separable in their pharmacological signature, and this separation is among the most important observations in the index case. TLR blockade — via Fucoidan or Omega-3 fatty acids — collapsed muscle tension immediately and simultaneously produced weakness. The interpretation: the neural input was cut, and the motor neuron lost both its excitatory tone and the signal maintaining neuromuscular function. Sucralose produces a different response. Sucralose inhibits T-cell proliferation via calcium signaling suppression, selectively reducing TH17 activity [10]. In the index case, sucralose reduced chronic overstimulation — but produced no weakness. The excitatory tone from the cross-reactive immune attack fell away; the neural afferent input through the vagus remained intact and continued to sustain neuromuscular function.

Two substances, two different receptor-level mechanisms, two qualitatively different clinical responses. This dissociation is consistent with two independent sources of motor neuron excitation operating simultaneously — one neural, one immunological.

It follows that the immunological component depends on residual adaptive immune function. As mycotoxin burden rises and T-cell activity is progressively suppressed, this second mechanism weakens. In the later phase of the index case — with CD25 at 1.0–3.1% against a reference range of 13–24% — the cross-reactive T-cell attack has largely collapsed. What remains is the neural mechanism alone: mycotoxin-driven vagal afferent overactivation maintaining residual motor neuron tone, without the additional excitatory contribution of the immune component.

2.3. The Third Trigger: Dectin-1 and the Inflammatory Switch

Level 3 — Nerve Inflammation

The two mechanisms described above — vagal afferent spill-over and cross-reactive immune attack — share a common precondition: the biofilm is intact. As long as the biofilm holds, the fungus is concealed, beta-glucan is shielded from immune recognition, and the system remains in the chronic, low-grade state described in Section 2.1 and Section 2.2. When the biofilm ruptures, due to antifungal agents such as nystatin, the dynamics change.

Beta-glucan — the primary structural component of the fungal cell wall — is normally hidden behind the biofilm and therefore invisible to the pattern recognition receptors that would respond to it. When an antifungal agent, an enzymatic preparation, or mechanical disruption breaks the biofilm open, beta-glucan is suddenly exposed. It activates Dectin-1, a C-type lectin receptor expressed on microglia, macrophages, and dendritic cells, triggering a Syk-CARD9 signaling cascade that drives acute neuroinflammation [8].

This produces a qualitatively different clinical state — not the sustained tonic tension of the TLR phase, but a spreading inflammatory response. In the index case, this manifested as burning nerve pain originating in the spine and partially migrating into the arms over several weeks.

The clinical course alternates between phases. When the biofilm is intact: TLR-driven vagal afferent signaling dominates, cross-reactive T-cell overstimulation is present if immune function permits, and the presentation is tonic muscle tension with fasciculations. When the biofilm ruptures: Dectin-1 activates, the presentation shifts to inflammatory nerve pain spreading along active motor tracts. When the biofilm regrows: the system returns to the TLR phase.

Each disruption-and-regrowth cycle extends the inflammatory front further along the neural axis — a ratchet mechanism that does not reset between cycles.

This cycling also offers a candidate explanation for the segmental spread pattern characteristic of ALS. Progression does not require the fungus to spread. It requires only that each biofilm rupture exposes a new edge of beta-glucan to Dectin-1 recognition — driving neuroinflammation into motor territories. The spread is not anatomical migration of a pathogen. It is the stepwise failure of adjacent neural territories to withstand repeated inflammatory cycles.

2.4. The Core Paradox

The three mechanisms described above produce an outcome that is, on its face, contradictory.

The fungal colonization that is making the patient ill is simultaneously keeping his motor neurons alive.

The mycotoxins suppress the adaptive immune system severely enough to prevent fungal elimination — but in doing so, they maintain the afferent input that motor neurons have calibrated to as their functional baseline. As long as the fungus is present, the vagal afferent signal continues. As long as that signal continues, the motor neurons remain under tonic excitation.

The hypothesis suggests a potentially viable treatment strategy consisting of two sequential stages. First: eliminate the fungus completely — disrupting the biofilm, exposing the organism, destroying it. Second: replace the lost afferent input synthetically — maintaining motor neuron excitatory tone through an artificial TLR signal.

3. Case Documentation

Scope Statement

This document does not claim: (a) formal ALS diagnosis — the current clinical diagnosis is Cramp-Fasciculation Syndrome (R25.3); (b) proof of the proposed hypothesis — the mechanistic chain is stated as hypothesis supported by internally consistent observations and external analogical evidence; (c) recommendation for self-treatment — none of the interventions described should be replicated without medical supervision; (d) generalizability — the observations derive from a single patient and require validation in independent cohorts.

What this document does claim: a reproducible, internally consistent pattern of pharmacological responses, laboratory findings, and clinical events that is not explained by any established diagnostic framework, and that warrants formal investigation under the proposed mechanistic hypothesis.

3.1. Laboratory Findings

Mycotoxin findings

Trichothecene/T-2 toxin in urine (IMD Berlin ELISA panel): five positive results across independent assays, including one conducted after a 32-hour fast — establishing an internal rather than dietary source. Note: the assay does not distinguish T-2 from Satratoxins; both read as T-2-like. LTT testing for Stachybotrys was negative, providing no evidence of detectable T-cell sensitization in this assay; this result does not exclude previous exposure or colonization;

Urinary mycotoxin profiles diverge by disruption site: biofilm disruption in the stomach (agents taken with food) raises T-2; disruption in the intestine (same agents taken fasted, bypassing the stomach) raises Fumonisin while T-2 simultaneously falls. The findings suggest two mold-associated toxins originating from anatomically distinct colonization sites. This site-specificity is directly testable via sequential disruption protocols with pre- and post-urinary mycotoxin analysis.

Five upper endoscopies performed: fungus not directly identified, consistent with biofilm-protected colonization. Mild chronic gastritis was documented at each examination without identified etiology and without further investigation. An organism concealed behind a biofilm would not be visible on white-light endoscopy; its sustained mucosal effect — chronic low-grade inflammation — would be. The absence of follow-up investigation into unexplained chronic gastritis in a male in his mid-thirties across five sequential examinations represents a missed diagnostic opportunity under the proposed framework.

Immunological findings — six assessments over 17 months, including five CD25 measurements

CD25 (IL-2 receptor / T-cell activation gate): April 2025: 2.9%; May 2025: 2.5%; June 2025: 3.1%; October 2025: 2.0%; March 2026: 1.0%. Reference: 13–24%. Consistently 80–90% below the lower reference limit across all measurements.

Activated T-lymphocytes (HLA-DR+): 2.3–3.5% across four assessments. Reference: 5–12%.

Cytokine profile — multiple measured T-cell-associated cytokine responses were below the laboratory reference ranges: IFN-γ (TH1) 79.5 pg/ml (reference ≥118); IL-17 (TH17) 5.4 pg/ml (reference ≥9.6); IL-10 (T-reg) 135 pg/ml (reference ≥353); IL-4 (TH2) 16.7 pg/ml (reference ≥30).

This is not an autoimmune shift — where the immune system moves in one direction while another rises. Here every axis is suppressed simultaneously. This matches the documented profile of Trichothecene mycotoxins: global inhibition of hematopoietic and lymphatic cells without selective imbalance [13].

Monocytes persistently elevated: 11.0–12.4% across three assessments (reference <10%) — consistent with chronic antigen exposure in the absence of an adequate T-cell response. CD8+ T-cells reduced; central memory T-cells reduced; NK-cell function and granulocyte function normal — confirming a selective adaptive T-cell activation deficit, not a general immune failure.

Biochemical findings

Vitamin B6: 1.83 µg/l (reference ≥10.1) — less than one-fifth of the lower reference limit. Kynurenine: 2.45 µmol/l (reference 1.00–2.00) — elevated, confirming tryptophan diversion away from serotonin synthesis. IDO activity within normal range (ratio 1.1 vs. <1.6) — indicating impaired peripheral B6-dependent conversion as the driver of kynurenine elevation, not central IDO overactivation.

Neurological findings

EMG (Institution A, May 2022): neurogenic remodeling in all tested muscles bilaterally. Pathological spontaneous activity present only in right M. abductor pollicis brevis.

EMG (Institution B, July 2022): isolated right M. tibialis anterior involvement — stabilization confirmed two months after high-dose NR and TUDCA were added.

CSF (Institution A, May 2022): leukocytes 2/µl, total protein 428 mg/l (reference upper limit ~450 mg/l), lactate 1.5 mmol/l, no blood-brain barrier disturbance. Absence of CSF pleocytosis excludes classical inflammatory CNS disease — consistent with the proposed non-inflammatory motor neuron hyperexcitability mechanism.

Neurofilament light chain (NfL) in serum: unremarkable at two timepoints (May 2022, February 2023). Normal NfL in the presence of EMG-confirmed neurogenic remodeling distinguishes this presentation from classical rapidly progressive ALS at the biomarker level — consistent with sustained motor neuron hyperexcitability rather than acute axonal destruction.

Monopedal hopping asymmetry (Institution C, October 2024): left 10/10, right 5/10 — objective clinical documentation of persistent right-sided motor deficit.

3.2. Pharmacological Response Documentation

Over thirty distinct pharmacological observations were documented across five years. The most mechanistically significant are grouped below by the pathway they implicate.

TLR modulation — direct motor tension response

Fucoidan (TLR modulator): complete loss of muscle tension within five minutes, simultaneous onset of weakness. Reproducible across multiple trials. Omega-3 fatty acids: identical response. Two structurally unrelated substances, same receptor pathway, same immediate effect — the strongest available observational evidence for TLR-mediated motor neuron tension maintenance. When the afferent input is blocked, the motor neuron loses both its excitatory tone and neuromuscular function simultaneously.

Clinical warning: Omega-3 supplementation is routinely recommended to ALS patients for neuroprotective and anti-inflammatory properties. In the proposed mycotoxin-driven subgroup, Omega-3 acts as a TLR2/TLR4 inhibitor [15] — blocking the exact pathway maintaining motor neuron tone. The documented effect — immediate tension collapse followed by weakness — suggests that standard supplementation protocols may be actively harmful in this subgroup. Stratification by mycotoxin status before supplement recommendation has not been investigated.

T-cell suppression — tension reduction without weakness

Sucralose inhibits T-cell proliferation via calcium signaling suppression, selectively reducing TH17 activity [10]. In the index case, sucralose reduced motor tension without producing weakness — in direct contrast to TLR blockade, which collapsed tension and triggered weakness simultaneously. The immunological component of motor neuron excitation was reduced; the neural afferent component remained intact. This dissociation is the pharmacological evidence that two independent mechanisms are operating in parallel.

Mirtazapine — documented paradoxical dual effect

Two mechanisms operated simultaneously. First: H1 blockade releases TH17 suppression, increasing IFN-γ, IL-17, and IL-2 — amplifying the TLR signal so that motor neurons remain under excitatory tone. Second: the same H1 blockade suppresses the local mucosal inflammatory response through potent H1-receptor antagonism — reducing vasodilation and immune cell recruitment at the gastric mucosa, making the fungus less effectively repelled. Mirtazapine maintained motor neuron stability by sustaining the fungal colonization driving the pathological process.

Biofilm disruption — TUDCA, NR, and the Dectin-1 response

TUDCA modulates bile acid receptor signaling in the upper gastrointestinal tract, altering local pH and mucosal conditions in a way that directly stresses a biofilm-protected fungal colony. NR elevates NAD+ and activates SIRT enzymes that enhance macrophage antifungal activity. Together, added between May and July 2022, they are proposed to have maintained sustained low-grade biofilm disruption and immune activation — the period of documented EMG stabilization. The neuroprotection observed was likely a consequence of sustained motor neuron tension maintenance, not a direct pharmacological action on the neurons themselves.

When the biofilm disrupts acutely — as documented under Nystatin and other antifungal agents — the Dectin-1 response activates: spinal pain reported to spread from the spine into the arms.

3.3. Systematically Excluded Diagnoses

The following categories have been formally excluded across four institutions over three years (Institution A 2022; Institution B 2022, 2023, 2024; Institution C 2024):

Structural: cMRT brain unremarkable; MRT thoracic, lumbar, and cervical spine unremarkable (minor disc findings at HWK 5–6 and HWK 6–7 without stenosis or myelopathy, considered incidental).

Electrophysiological: Somatosensory evoked potentials normal bilaterally at all timepoints — excludes sensory tract involvement and demyelinating pathology. Nerve conduction velocity normal — excludes peripheral neuropathy.

Genetic: Myopathy and muscular dystrophy panel unremarkable; SMN1 analysis unremarkable (excludes SMA); AR-repeat analysis unremarkable (excludes Kennedy disease).

Autoimmune: ANA, ANCA, PR3, MPO antibodies negative; antineuronal antibodies in serum and CSF negative; potassium channel antibodies (VGKC/CASPR2/LGI1) negative; anti-ganglioside antibody screening negative.

Metabolic: Morbus Pompe (acid alpha-glucosidase deficiency) negative.

The systematic exclusion of structural, electrophysiological, genetic, autoimmune, and metabolic diagnoses across four institutions over three years leaves no established diagnostic framework that accounts for the complete clinical picture. The combination of EMG-confirmed neurogenic remodeling, documented global immunosuppression across all antifungal axes, five positive urinary mycotoxin assays, and over thirty reproducible pharmacological responses consistent with a single proposed mechanism represents a coherent alternative hypothesis that has not been formally investigated by any treating institution.

3.4. Supplementary Biochemical Observations

The following findings are documented as additional biochemical observations consistent with the proposed mechanism but not part of the central mechanistic argument. They are presented separately to preserve the clarity of the core hypothesis.

Serotonin pathway disruption. Approximately 95% of systemic serotonin is produced in the enterochromaffin cells of the intestinal mucosa — the same mucosal surface proposed to be overgrown by the colonizing biofilm. Serotonin serves as a direct cofactor for T-cell activation, upregulating CD25 expression. Biofilm-mediated disruption of enterochromaffin cell function would reduce serotonin output, suppress CD25, and impair T-cell activation — providing a secondary mechanism for the global immunosuppression documented in the index case, alongside the direct Trichothecene-mediated T-cell inhibition.

Kynurenine pathway diversion. Kynurenine measured at 2.45 µmol/l (reference 1.00–2.00) with IDO activity within normal range (ratio 1.1 vs. <1.6) indicates impaired peripheral B6-dependent tryptophan-to-serotonin conversion rather than central IDO overactivation. Vitamin B6 measured at 1.83 µg/l (reference ≥10.1) — less than one-fifth of the lower limit — confirms the enzymatic block. The downstream product of this diversion, quinolinic acid, is an NMDA receptor agonist with excitotoxic potential [30], documented in ALS CNS tissue. This metabolic shift is consistent with the proposed colonization and represents an independent biochemical corroborating finding.

Reid concordance. Reid’s proposed diagnostic criteria for mycotoxin-driven ALS include mycotoxin detection, immune paralysis, and neurogenic damage [3]. The serotonin-pathway disruption and kynurenine elevation documented here are consistent with the immune paralysis criterion and extend the biochemical picture Reid described in his cohort.

4. Supporting Evidence from the Literature

The following evidence sources were identified independently of the case documented in Section 3. Each is cited for the specific mechanistic or epidemiological claim it supports; none establishes the complete causal chain proposed in this hypothesis. Together, they constitute a convergent body of literature that has not previously been assembled in relation to a unified mycotoxin-driven mechanism.

4.1. External Epidemiological and Pharmacological Evidence

Montchavin cluster — Lagrange et al. (J Neurol Sci, 2021) [2]. Fourteen ALS cases in a single French mountain village between 1990 and 2018, against a statistically expected count of one. No shared genetic factor. All affected individuals had consumed wild-harvested fungi with documented neurotoxic potential. Under the proposed mechanism, the exposure-active phase — fungi present, toxins circulating, vagal afferent signal sustained — maintained motor neuron viability. When exposure ended, the signal collapsed.

Reid (2006/2021) [3]. Reid proposed three diagnostic criteria for mycotoxin-driven ALS: mycotoxin detection, immune paralysis, and neurogenic damage. All three are fulfilled in the index case, as documented in Section 3. Reid’s criteria were not known to the index patient at the time the observations were made; their retrospective fulfillment represents independent convergence, not circular reasoning.

Ustekinumab FAERS disproportionality — Gaimari et al. (2022) [4]. Ustekinumab blocks IL-12 and IL-23, the cytokines driving TH1 and TH17 differentiation. A FAERS disproportionality analysis identified an elevated ALS reporting signal in association with ustekinumab [4]. This association is hypothesis-generating and does not establish causality. This is the pharmacological inverse of the proposed mechanism: deliberately suppressing antifungal immunity produces the same downstream risk as the mycotoxin-driven immune suppression described here.

4.2. Immunological Evidence in ALS

TH17 in ALS cerebrospinal fluid — Rentzos et al. (2010) [26]; meta-analysis (J Neuroinflammation, 2026) [11]. IL-17 and IL-23 are significantly elevated in the CSF of ALS patients — active TH17 engagement within the CNS compartment, not only peripherally. A 2026 meta-analysis confirms TH1 and TH17 elevation in blood, CSF, and CNS tissue in ALS, with higher TH17 relative to regulatory T-cells correlating with more aggressive progression. TH17 is the primary antifungal cytokine axis. What antigen is driving this response centrally has not been identified. The present hypothesis offers a candidate.

Anti-LRP4 antibodies [27]. Anti-LRP4 IgG antibodies — targeting a receptor expressed on motor neuron surfaces — are detected in 10–23% of ALS patients across multiple independent cohorts. The presence of measurable autoantibodies against a motor neuron surface protein is inconsistent with a purely neurodegenerative etiology. Molecular mimicry between fungal surface antigens and motor neuron surface proteins is a mechanistically complete candidate explanation for their origin.

Passive transfer studies [28]. Passive-transfer experiments have reported abnormal calcium accumulation and motor-neuron damage in animals receiving serum or purified IgG from subsets of ALS patients [28]. These findings suggest that circulating immune factors may contribute to neuronal injury, although the responsible targets and their clinical relevance remain uncertain. An immune component of ALS patient serum is sufficient to reproduce motor neuron pathology in naive animals. What primed the immune system to produce these antibodies remains unidentified.

NK cell elevation in ALS — Piccoli et al. (BMC Neurology, 2023) [18]; Murdock et al. (JCI Insight, 2021) [19]; Garofalo et al. (Nature Communications, 2020) [5]. NK cells contribute to innate immune surveillance and can participate in antifungal defense. Altered NK-cell numbers or phenotypes have been reported in ALS cohorts. Piccoli et al. found increased circulating NK-cell numbers in 92 patients with sporadic ALS [18]. Garofalo et al. detected NK cells in post-mortem ALS motor cortex and spinal cord tissue and reported NKG2D-ligand expression on motor neurons [5]. Murdock et al. subsequently identified alterations in circulating NK-cell markers associated with ALS progression in sex- and age-dependent analyses [19]. Under the proposed hypothesis, these findings are compatible with, but do not establish, a response to chronic fungal antigen exposure.

Fungal components in ALS CNS tissue — Alonso, Pisa et al. (2015) [29]. Fungal DNA, fungal antigens, and fungal proteins detected in CSF and post-mortem brain tissue from ALS patients using PCR, proteomics, and immunohistochemistry — in a pattern distinct from non-neurological controls. The findings have not been broadly replicated and are cited here as independent external corroboration that fungal components can reach the ALS central nervous system.

4.3. Mechanistic Literature

Vagal afferent projections — Pharmacological Research (2025) [6]. Systematic description of afferent vagal projections from the upper gastrointestinal tract to the NTS and adjacent brainstem motor nuclei — the precise anatomical route proposed in Section 2.1. Vagal nerve atrophy has additionally been documented by ultrasound in ALS patients [17]; intestinal interoceptive dysfunction has been proposed as a related upstream mechanism [16]. Under the proposed framework, vagal atrophy represents an upstream lesion consistent with sustained high-amplitude afferent firing, not a downstream consequence of motor neuron loss.

TLR signaling on neurons — Liu et al. (2012) [20]. TLR receptors are expressed on neuronal membranes and generate excitatory signals when activated by PAMPs — the receptor-level mechanism for the vagal afferent overactivation described in Section 2.1.

IFN-β and PKC — Reetz et al. (J Neuroinflammation, 2014). IFN-β increases neuronal excitability via protein kinase C activation [14] — a secondary amplification pathway reinforcing the primary afferent signal under sustained TLR activation.

Type-I Interferon paradox — Carletta et al. (Brain, 2026) [25]. Hyperactivation of the Type-I Interferon signaling pathway documented across sporadic, C9orf72, and SOD1 ALS subtypes; 23 interferon-stimulated genes significantly upregulated, six correlating negatively with age of death. The present hypothesis describes the same IFN-β pathway as maintaining motor neuron excitability via PKC — paradoxically protective in the mycotoxin-driven subgroup. The Carletta study does not ask why the IFN pathway is activated in the first place. A gastric fungus sending persistent TLR and dsRNA-pattern signals is a mechanistically complete candidate explanation. Inhibiting IFN without eliminating the upstream signal addresses the effect, not the cause.

Dectin-1 and neuroinflammation — Baldwin et al. (PNAS, 2015) [8]. Beta-glucan/Dectin-1 signaling enables CNS neuroinflammation via microglial activation — the receptor-level mechanism for the inflammatory switch described in Section 2.3.

Molecular mimicry — Martini et al. (Nature Medicine, 2023) [7]. Cross-reactive T-cell responses between microbial antigens and self-structures documented in autoimmune conditions — the mechanistic precedent for the cross-reactive immune attack proposed in Section 2.2.

Kynurenine pathway in ALS — Guillemin et al. (2019) [30]. Elevated quinolinic acid — an NMDA-receptor excitotoxin — documented in CNS tissue of ALS patients. The same metabolic shift is biochemically confirmed in the index case, establishing that this is not an idiosyncratic individual finding but a pattern present across ALS patients at the tissue level.

T-2 toxin and blood-brain barrier permeability [21]. T-2 Trichothecene disrupts the blood-brain barrier at low nanomolar concentrations in vitro. An analogous effect at the blood-spinal cord barrier would provide a candidate explanation for the segmental rostro-caudal spread pattern of ALS — the barrier opening under sustained mycotoxin pressure, region by region, as cumulative toxin load exceeds local barrier integrity thresholds.

4.4. Therapeutic Evidence

Masitinib long-term survival — Ludolph et al. (medRxiv, April 2026) [12]. Masitinib inhibits mast cells and microglia — both responding to fungal antigens via Dectin-1 and TLR. In a defined subgroup where progression is driven primarily by microglial and mast cell activity, long-term survivors showed median survival of 121 months against a projected 42 months [12]. Under the proposed hypothesis, this could be the subgroup in which fungal antigen-driven microglial activation dominates — and in which mycotoxin testing has not been performed. Masitinib may be addressing the downstream inflammatory consequence of a fungal source that has never been identified upstream.

Ustekinumab as therapeutic inverse. Pharmacological suppression of TH1 and TH17 associates with an elevated ALS reporting signal. This is the mirror image of a treatment implication: restoring TH1 and TH17 function in mycotoxin-suppressed patients represents a candidate therapeutic direction that has not been investigated.

5. Therapeutic Outlook and Proposed Diagnostic Steps

5.1. The Current Situation

The index patient has been stable for four years. Stable does not mean well. CD25 at 1.0% as of March 2026 — the lowest measurement to date — indicates progressive deepening of immune suppression. The neural mechanism described in Section 2.1 is maintaining residual motor neuron tone. The immune-mediated component of motor-neuron overstimulation described in Section 2.2 has largely collapsed. The fungus is still present. The equilibrium is fragile and its direction is known.

5.2. Proposed Diagnostic Protocol

The following investigations are proposed as a first-tier diagnostic screen in ALS patients — particularly those with early or atypical presentations, stable disease course, or unexplained immunological findings. All are commercially available. None requires specialist infrastructure beyond a standard neurological center.

Urinary mycotoxin screening. ELISA-based Trichothecene panel. Minimum two tests, conducted on separate occasions, with at least one after a minimum 24-hour fast. A positive result after prolonged fasting establishes an internal rather than dietary source — the critical distinction. Simultaneous cellular immune status assessment: activated T-cells, CD25, IFN-γ, IL-17, IL-10. A combination of mycotoxin positivity with global suppression of all antifungal immune axes constitutes the core diagnostic signature proposed here.

Lymphocyte transformation test — Mold. LTT against selected mold antigens could be explored as a measure of cellular sensitization. Its sensitivity, specificity, and ability to distinguish previous exposure from active colonization would require validation for this application.

Contrast sensitivity screening. Visual contrast sensitivity (VCS test) as a validated, low-cost biomarker for biotoxin-mediated neurological disease. Available as a standardized online protocol. Abnormal VCS in the absence of ophthalmological pathology is a documented signal in chronic biotoxin exposure and can be incorporated into routine assessment.

Biofilm-directed endoscopy. Upper endoscopy with mucolytic pre-treatment (e.g. N-acetylcysteine), targeted brush cytology from the gastric fundus, and mucosal biopsies from the suspected colonization site. PCR on biopsy material targeting Trichothecene-producing species: Fusarium, Myrothecium, Trichoderma, Memnoniella, Trichothecium. Standard culture and antigen detection in parallel. Probe-based confocal laser endomicroscopy (PCLE) as real-time in vivo microscopy as a candidate approach for direct visualization.

Serotonin and kynurenine pathway assessment. Urinary or serum kynurenine, tryptophan, and the kynurenine/tryptophan ratio. Vitamin B6 (pyridoxal-5-phosphate). IDO activity index. A pattern of elevated kynurenine with depleted B6 and normal IDO activity indicates peripheral enzymatic block on the serotonin synthesis pathway — the specific biochemical profile documented in the index case and consistent with biofilm-mediated enterochromaffin disruption.

5.3. Synthetic TLR Signal Replacement

Once the fungus is eliminated, the natural afferent input through the vagal TLR pathway disappears. A candidate approach: a nanoparticle delivery system carrying a weak TLR agonist applied to the gastric mucosa, titrated downward over weeks to months as motor neuron tone is monitored electrophysiologically. Whether motor neuron homeostatic recalibration is achievable over a clinically viable timeframe remains unknown.

These research questions can be investigated using currently available technologies. The diagnostic protocol proposed in Section 5.2 could be implemented in any ALS center within the current standard of care. The first publication of results — positive or negative — would constitute the first formal test of the hypothesis.

6. Closing Statement

The author holds no medical degree, no institutional affiliation, and received no external funding for this work. All laboratory investigations were self-funded. All pharmacological observations were self-conducted and documented contemporaneously over five years.

The observations presented in this document were not made to construct a hypothesis. The hypothesis was constructed because the observations demanded an explanation that no existing diagnostic framework provided. The pharmacological responses described in Section 3.2 were not designed experiments. They were prospectively documented responses to substances taken for other purposes, which only later revealed a consistent mechanistic pattern. Mirtazapine was prescribed for anxiety. Fucoidan was taken as an antifungal agent. The five-minute collapse of muscle tension that followed its administration was not anticipated. The simultaneous onset of weakness when TLR was blocked was not anticipated. Each observation was recorded as it occurred.

The mechanistic interpretation presented here may be incomplete. The index case may not be generalizable. These are legitimate scientific limitations and they are acknowledged. What the data do not support is the continued absence of formal investigation. Five years of prospectively documented observations, five positive urinary mycotoxin assays from an internal source, six immunological assessments demonstrating the same suppression pattern across seventeen months, over thirty reproducible pharmacological responses consistent with a single mechanistic framework, and formal diagnostic exclusion across four institutions constitute a structured evidential basis that warrants examination.

Ethics and Consent Statement: This manuscript presents retrospective self-documentation by the author. No additional participants were involved. Explicit consent is provided for publication of the clinical information included in the manuscript. No prospective interventional clinical study was conducted.

Data Availability: All laboratory reports, pharmacological-response documentation, and supporting materials are available from the corresponding author upon reasonable request.

Appendix A.1 — Motor Signs Preceding the Documented Onset

The official symptom onset is July 2021. Retrospective review suggests motor involvement began earlier — possibly significantly earlier.

From early 2020, restless legs were present most evenings: not pain, but a compulsive urge to move, with a sensation of low electrical current running through the limbs. In spring 2020, an episode of intense diaphragmatic burning occurred — interpreted at the time as a COVID-related respiratory event; it was not. Under the proposed mechanism, both are consistent with early TLR-driven motor neuron hyperexcitability: the colonization and cross-reactive signaling were already active before overt fasciculations began.

An inability to fall asleep without eating first, persisting for approximately 17 years. Proposed interpretation: gastric acid introduced with each meal briefly stressed the colonizing fungus, triggering a transient mycotoxin pulse that momentarily reduced the vagal afferent alarm signal, permitting sleep onset. If correct, this observation is independently consistent with a colonization predating the motor symptoms by at least 11 years.

A first BioNTech vaccination in June 2021 produced disproportionate symptoms — three days of intense cranial pressure, neck pain, back pain, and dizziness. The proposed interpretation: the vaccine acted as an adjuvant, amplifying a TLR signal that was already running. The resulting headaches, present since that event, remain coupled to the same immune signal four years later.

Appendix A.2 — Cross-Reactivity Beyond Motor Neurons

The immune cross-reaction is not proposed to be motor-neuron-specific. It is proposed to be nerve-surface-specific — targeting whichever nerve territory is most active at a given time.

Progressive night-vision impairment has been documented over several years, requiring visual reference points (e.g. the tail lights of a preceding vehicle) to better navigate in darkness. The pattern follows the same logic as motor involvement: when the optic system is actively engaged, cross-reactive signaling concentrates there. Eating produces partial improvement within approximately 30 minutes — consistent with gastric acid stressing the colonizing fungus, triggering a mycotoxin pulse that transiently suppresses mucosal immunity and interrupts the cross-reactive signal.

Recurring left-sided chest pain follows the same anatomical and pharmacological logic. The cardiovascular system is also innervated by the vagus nerve.

Punctate needle-like sensory stinging, sudden and point-specific, in the distal extremities — consistent with cross-reactive immune activity on sensory nerve surfaces without motor involvement.

The previously described headaches and cranial pressure could also have a vagal origin within the proposed model.

Appendix A.3 — The Bidirectional Cross-Reaction: Conscious Motor Activation as an Immune Trigger

From October 2025 onward, the following pattern could be predicted to the second: conscious attention directed to breathing — not deep inhalation, not hyperventilation, but merely shifting cognitive focus to the respiratory process — triggered within seconds a full cross-reactive cascade: dizziness, chest pain, occasionally severe enough to require sitting down, vagal hyperstimulation and an activation of the mucosal immune layer.

During sleep, this did not occur. The immune system worked autonomously against the fungus overnight, without motor interference. During waking hours, an activation of the conscious motor system — especially the respiratory motor system — sent a signal to the mucosal immune layer that switched the fungus into defensive mycotoxin production.

The same cascade followed any brief sympathetic activation: startle responses and acute stress reflexes of a few seconds duration were sufficient to trigger fasciculations and the characteristic epigastric sensation identified over years as mucosal immune activation. The proposed mechanism: cortical alarm activates descending sympathetic pathways through the brainstem, engaging efferent vagal fibers; the vagus returns a stress signal to the gastric mucosa within seconds; TLR activation follows.

This mechanism makes the 2020 pandemic period mechanistically interpretable. Months of sustained breath-holding at checkouts, in stairwells — hundreds of daily brief sympathetic activations — may have repeatedly triggered the mucosal immune response or contributed to the initial development of the proposed cross-reaction. The diaphragmatic burning episode documented in spring 2020 is, in retrospect, consistent with the cross-reaction crossing into respiratory motor territory at that time.

Mirtazapine interrupted this cycle. By maintaining sustained low-level TLR activation independently of motor activity, it eliminated the peak-and-trough pattern driven by conscious motor engagement. The fungus could not hide during quiet periods because TLR was never fully off. The tradeoff — sustained mucosal H1 blockade reducing local antifungal immune recruitment — is described in Section 3.2.

Activity-dependent redistribution following biofilm disruption:

A reproducible observation emerged particularly during periods of recent biofilm disruption. Rather than remaining confined to a fixed anatomical region, muscle tension, fasciculations, cramps, and perceived motor hyperexcitability frequently shifted toward the motor system that had been most actively engaged immediately beforehand.

During cycling, increased tension often concentrated around the eyebrow and periorbital musculature. During eating, chewing, tongue movement, and swallowing, tension shifted toward the tongue, masseter muscles, and pharyngeal musculature. During prolonged walking, the dominant tension localized to the legs. During writing or keyboard use, it concentrated in the fingers and forearm muscles. Conscious attention directed toward breathing could shift the phenomenon toward the diaphragm and phrenic nerve territory within seconds.

Importantly, this redistribution was observed most prominently following partial biofilm disruption, when inflammatory activity appeared to be increased. The phenomenon did not resemble fixed progression. Instead, it behaved as a dynamic relocation of motor hyperexcitability into the motor pathways that had been most recently activated. Under the proposed mechanism, recently active motor circuits may be preferentially affected during the post-disruption phase, resulting in a temporary redistribution of symptoms without requiring anatomical spread of the underlying process.

Appendix A.4 — The Oral Cavity as a Second Source

Nystatin placed on the tongue only — not swallowed — produced muscle tension relief within seconds, replicating the response observed with ingested Nystatin acting on the upper gastric mucosa. The hypoglossal nucleus in the medulla oblongata sits in immediate proximity to the nucleus ambiguus and the dorsal motor nucleus of the vagus — the same brainstem region receiving afferent input from the gastric colonization — providing the anatomical basis for two distinct mucosal sources converging on the same motor territory.

Appendix A.5 — Immune Collapse: Clinical Manifestations

The immunological values documented in Section 3.1 — CD25 at 1.0–3.1%, with IFN-γ and IL-17 below their reference minima — manifest clinically as a pattern that is difficult to attribute to coincidence.

A urinary tract infection confirmed by culture produced no urinary leukocytes on dipstick testing — active pathogen, no cellular immune response deployed. A recurrent suppurative furuncle at the same finger location resolved, recurred, resolved, recurred — three cycles — before surgical removal. Three to four hordeola simultaneously on the eyelids, recurring cyclically; their frequency tracks precisely with periods of high mycotoxin burden, making them a usable clinical barometer. Elevated ALAT in April 2025, consistent with the documented hepatotoxicity of T-2 Trichothecene. Five upper respiratory infections in a three-month period. First documented herpes simplex reactivation.

One indirect marker of the expanding cross-reactive front: when probiotics were reintroduced after the six-antibiotic course in 2024, the resulting muscle tension was dramatically more intense than the same intervention had produced two years earlier — consistent with more nerve territories having been marked by Dectin-1-mediated neuroinflammation in the interim.

A colonization limited to the mucosal surface is a local problem. At the T-cell suppression levels documented here — specifically the CD4+ T-cell activation deficit, not neutropenia — the published literature on invasive fusariosis identifies this immune profile as a risk factor for systemic fungal dissemination should the mucosal barrier fail. This risk is noted for completeness and has been communicated to the treating physicians.

Appendix A.6 — Nutritional Patterns as Diagnostic Signals

Dietary sugar and refined carbohydrates consistently worsened motor symptoms, documented across multiple observations. Small quantities — a single piece of fruit — were sufficient to produce a reproducible response. The proposed mechanism: glucose is the primary metabolic substrate for the colonizing fungus; increased luminal glucose availability directly supports mycotoxin production and mucosal antigen load.

High dietary fat produces a different pattern: not increased tension but increased weakness, hand numbness, and leg cramping. The proposed explanation: dietary fat binds mycotoxins in the gastrointestinal lumen, transiently reducing systemic absorption and thereby reducing the afferent TLR signal that maintains motor neuron tone.

Appendix A.7 — Two Sites, Two Fungi, Two Toxin Profiles

The urinary mycotoxin patterns indicate at least two anatomically distinct colonization sites producing different toxin profiles.

Gastric disruption (biofilm-disrupting agents taken with food, acting on the stomach): Trichothecene/T-2 rises in urine; cross-reactive symptoms begin; palpation tenderness below the solar plexus at the gastric fundus location. Intestinal disruption (same agents taken fasted, bypassing the stomach into the small bowel): Fumonisin rises while T-2 simultaneously falls; painful small bowel inflammation occurs; no fasciculations, no cross-reaction on motor neurons.

When the immune system concentrates on the intestinal colonization, the gastric site experiences reduced immune pressure — T-2 falls as Fumonisin rises, and vice versa. The two sites appear to compete for immune resources, with the dominant immune response at one site temporarily suppressing response at the other.

This site-specificity is directly testable via sequential disruption protocols with pre- and post-urinary mycotoxin analysis — a protocol requiring no specialized infrastructure beyond ELISA-based urine mycotoxin testing.

Appendix A.8 — Serotonin as a Prerequisite for Antifungal Immunity

A reproducible two-step observation: Biofilm Defense alone produced minimal immune response. Biofilm Defense preceded by 5-HTP supplementation produced a strong, consistent immune response. The sequence was reproducible across multiple trials.

The proposed mechanism: serotonin upregulates CD25 expression on T-cells. Without adequate serotonin — blocked by both IDO-mediated tryptophan diversion and B6-depletion as documented in Section 3.4 — biofilm disruption exposes the fungus to an immune system that lacks the co-signal required to mount an effective T-cell response. Restoring serotonin precursor availability partially restores the T-cell activation threshold, allowing the immune system to respond to exposed fungal antigens.

This observation has direct implications for treatment sequencing: restoration of the serotonin synthesis pathway — addressing both the IDO block and the B6 deficit — may be a prerequisite for effective antifungal immune mobilization.

All observations documented in this appendix are reproducible and have been recorded contemporaneously. The mechanistic interpretations are hypotheses. This appendix completes the clinical picture — not as proof, but as an invitation to those who have the tools to examine it.